Literature DB >> 16101493

Inhibitor of the glutamate vesicular transporter (VGLUT).

Charles M Thompson1, Erin Davis, Christina N Carrigan, Holly D Cox, Richard J Bridges, John M Gerdes.   

Abstract

The vesicular glutamate transporter (VGLUT) is responsible for the uptake of the excitatory amino acid, L-glutamate, into synaptic vesicles. VGLUT activity is coupled to an electrochemical gradient driven by a vacuolar ATPase and stimulated by low Cl-. VGLUT has relatively low affinity (K(m) = 1-3 mM) for glutamate and is pharmacologically and structurally distinct from the Na+-dependent, excitatory amino acid transporters (EAATs) found on the plasma membrane. Because glutamatergic neurotransmission begins with vesicular release, compounds that block the uptake of glutamate into the vesicle may reduce excitotoxic events. Several classes of competitive VGLUT inhibitors have emerged including amino acids and amino acid analogs, fatty acids, azo dyes, quinolines and alkaloids. The potency with which these agents inhibit VGLUT varies from millimolar (amino acids) to nanomolar (azo dyes) concentrations. These inhibitors represent highly diverse structures and have collectively begun to reveal key pharmacophore elements that may elucidate the key interactions important to binding VGLUT. Using known inhibitor structures and preliminary molecular modeling, a VGLUT pharmacophore is presented that will aid in the design of new, highly potent and selective agents.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16101493     DOI: 10.2174/0929867054637635

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  28 in total

Review 1.  Vesicular nucleotide transporter (VNUT): appearance of an actress on the stage of purinergic signaling.

Authors:  Yoshinori Moriyama; Miki Hiasa; Shohei Sakamoto; Hiroshi Omote; Masatoshi Nomura
Journal:  Purinergic Signal       Date:  2017-06-14       Impact factor: 3.765

2.  Identification of a vesicular nucleotide transporter.

Authors:  Keisuke Sawada; Noriko Echigo; Narinobu Juge; Takaaki Miyaji; Masato Otsuka; Hiroshi Omote; Akitsugu Yamamoto; Yoshinori Moriyama
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-28       Impact factor: 11.205

3.  Use of the hydantoin isostere to produce inhibitors showing selectivity toward the vesicular glutamate transporter versus the obligate exchange transporter system x(c)(-).

Authors:  S Kaleem Ahmed; Jean-Louis G Etoga; Sarjubhai A Patel; Richard J Bridges; Charles M Thompson
Journal:  Bioorg Med Chem Lett       Date:  2011-05-14       Impact factor: 2.823

Review 4.  Targeting glutamatergic signaling for the development of novel therapeutics for mood disorders.

Authors:  Rodrigo Machado-Vieira; Giacomo Salvadore; Lobna A Ibrahim; Nancy Diaz-Granados; Carlos A Zarate
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

5.  Large structural change in isolated synaptic vesicles upon loading with neurotransmitter.

Authors:  Kristi L Budzinski; Richard W Allen; Bryant S Fujimoto; P Kensel-Hammes; David M Belnap; Sandra M Bajjalieh; Daniel T Chiu
Journal:  Biophys J       Date:  2009-11-04       Impact factor: 4.033

6.  The development of benzo- and naphtho-fused quinoline-2,4-dicarboxylic acids as vesicular glutamate transporter (VGLUT) inhibitors reveals a possible role for neuroactive steroids.

Authors:  Christina N Carrigan; Sarjubhai A Patel; Holly D Cox; Erin S Bolstad; John M Gerdes; Wesley E Smith; Richard J Bridges; Charles M Thompson
Journal:  Bioorg Med Chem Lett       Date:  2013-12-25       Impact factor: 2.823

Review 7.  Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders.

Authors:  Gerard Sanacora; Carlos A Zarate; John H Krystal; Husseini K Manji
Journal:  Nat Rev Drug Discov       Date:  2008-05       Impact factor: 84.694

8.  Efficient digestion and mass spectral analysis of vesicular glutamate transporter 1: a recombinant membrane protein expressed in yeast.

Authors:  Holly D Cox; Chih-Kai Chao; Sarjubhai A Patel; Charles M Thompson
Journal:  J Proteome Res       Date:  2008-01-08       Impact factor: 4.466

9.  Tetrapeptide inhibitors of the glutamate vesicular transporter (VGLUT).

Authors:  Sarjubhai A Patel; Jon O Nagy; Erin D Bolstad; John M Gerdes; Charles M Thompson
Journal:  Bioorg Med Chem Lett       Date:  2007-07-26       Impact factor: 2.823

10.  Docking and homology modeling explain inhibition of the human vesicular glutamate transporters.

Authors:  Jonas Almqvist; Yafei Huang; Aatto Laaksonen; Da-Neng Wang; Sven Hovmöller
Journal:  Protein Sci       Date:  2007-07-27       Impact factor: 6.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.